Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Daniels VW"'
Autor:
Jovanović B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Temko D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA., Stevens LE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Seehawer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Fassl A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA., Murphy K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Anand J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Garza K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gulvady A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Harper NW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Daniels VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Xiao-Yun H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ge JY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115, USA., Alečković M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Pyrdol J; Departments of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Departments of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA., Hinohara K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Egri SB; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA., Papanastasiou M; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA., Vadhi R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Font-Tello A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Witwicki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Peluffo G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Trinh A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Shu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Diciaccio B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ekram MB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Subedee A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Herbert ZT; Department of Molecular Biology Core Facility, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Wucherpfennig KW; Departments of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Departments of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA., Letai AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Jaffe JD; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA., Sicinski P; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA., Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA., Dillon D; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Michor F; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: michor@jimmy.harvard.edu., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: kornelia_polyak@dfci.harvard.edu.
Publikováno v:
Cell reports [Cell Rep] 2023 Dec 26; Vol. 42 (12), pp. 113564. Date of Electronic Publication: 2023 Dec 14.
Autor:
Daniels VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Ludwig Center at Harvard, Boston, MA 02215, USA., Zoeller JJ; Ludwig Center at Harvard, Boston, MA 02215, USA.; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA., van Gastel N; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA., McQueeney KE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Parvin S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Potter DS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Fell GG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ferreira VG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, SP 13568-250, Brazil.; Instituto Nacional de Ciência e Tecnologia de Bioanalítica, INCTBio, Campinas, SP 13083-970, Brazil., Yilma B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gupta R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Spetz J; Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA 02215, USA., Bhola PD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Endress JE; Ludwig Center at Harvard, Boston, MA 02215, USA.; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA., Harris IS; Ludwig Center at Harvard, Boston, MA 02215, USA.; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA.; Department of Biomedical Genetics and Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14642, USA., Carrilho E; Instituto de Química de São Carlos, Universidade de São Paulo, São Carlos, SP 13568-250, Brazil.; Instituto Nacional de Ciência e Tecnologia de Bioanalítica, INCTBio, Campinas, SP 13083-970, Brazil., Sarosiek KA; Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA 02215, USA., Scadden DT; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.; Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA., Brugge JS; Ludwig Center at Harvard, Boston, MA 02215, USA.; Department of Cell Biology, Harvard Medical School, Boston, MA 02215, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. anthony_letai@dfci.harvard.edu.; Ludwig Center at Harvard, Boston, MA 02215, USA.
Publikováno v:
Science signaling [Sci Signal] 2021 Jun 08; Vol. 14 (686). Date of Electronic Publication: 2021 Jun 08.
Autor:
Watt AC; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Cejas P; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Translational Oncology Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.; CIBERONC CB16/12/00398, La Paz University Hospital, Madrid, Spain., DeCristo MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Metzger-Filho O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Lam EYN; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., BrinJones H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Kesten N; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Coulson R; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Font-Tello A; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Lim K; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Vadhi R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Daniels VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Montero J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Institute for Bioengineering of Catalonia, Barcelona, Spain., Taing L; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Meyer CA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA., Gilan O; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Bell CC; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia., Korthauer KD; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA., Giambartolomei C; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.; Istituto Italiano di Tecnologia (IIT), Genoa, Italy., Pasaniuc B; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Seo JH; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Freedman ML; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ma C; Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA., Ellis MJ; Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA., Krop I; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Winer E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Brown M; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Dawson MA; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia.; Centre for Cancer Research, University of Melbourne, Parkville, Victoria, Australia., Long HW; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. Henry_Long@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Henry_Long@dfci.harvard.edu., Zhao JJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. Jean_Zhao@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Jean_Zhao@dfci.harvard.edu.; The Broad Institute of MIT and Harvard, Cambridge, MA, USA. Jean_Zhao@dfci.harvard.edu., Goel S; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. shom.goel@petermac.org.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia. shom.goel@petermac.org.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. shom.goel@petermac.org.
Publikováno v:
Nature cancer [Nat Cancer] 2021 Jan; Vol. 2 (1), pp. 34-48. Date of Electronic Publication: 2020 Nov 09.
Autor:
Zoeller JJ; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA., Vagodny A; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA., Daniels VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Taneja K; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., Tan BY; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., DeRose YS; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Fujita M; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Welm AL; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Leverson JD; Oncology Development, AbbVie, North Chicago, IL, USA., Blot V; Oncology Development, AbbVie, North Chicago, IL, USA., Bronson RT; Department of Pathology, Harvard Medical School, Boston, MA, USA., Dillon DA; Department of Pathology, Brigham & Women's Hospital, Boston, MA, USA., Brugge JS; Department of Cell Biology and Ludwig Center at Harvard, Harvard Medical School, 240 Longwood Avenue, Boston, MA, 02115, USA. joan_brugge@hms.harvard.edu.
Publikováno v:
Breast cancer research : BCR [Breast Cancer Res] 2020 Nov 30; Vol. 22 (1), pp. 132. Date of Electronic Publication: 2020 Nov 30.
Autor:
Mai WX; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Gosa L; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Daniels VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ta L; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Tsang JE; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Higgins B; Pharma Research and Early Development, Roche Innovation Center, New York, New York, USA., Gilmore WB; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Bayley NA; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Harati MD; Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Lee JT; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Yong WH; Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Kornblum HI; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Bensinger SJ; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA.; Department of Microbiology, Immunology, and Molecular Genetics, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Mischel PS; Ludwig Institute for Cancer Research, University of California San Diego, San Diego, California, USA., Rao PN; Department of Pathology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Clark PM; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Cloughesy TF; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA.; Department of Neurology, David Geffen UCLA School of Medicine, Los Angeles, California, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Nathanson DA; Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA.; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, Los Angeles, California, USA.; Ahmanson Translational Imaging Division, David Geffen UCLA School of Medicine, Los Angeles, California, USA.
Publikováno v:
Nature medicine [Nat Med] 2017 Nov; Vol. 23 (11), pp. 1342-1351. Date of Electronic Publication: 2017 Oct 09.
Autor:
Khan NA; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Willemarck N; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Talebi A; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Marchand A; Cistim Leuven vzw, Bioincubator 2, 3001 Leuven, Belgium., Binda MM; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Dehairs J; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Rueda-Rincon N; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Daniels VW; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Bagadi M; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Thimiri Govinda Raj DB; European Molecular Biology Laboratory (EMBL), Grenoble Outstation and Unit of Virus Host-Cell Interactions (UVHCI), UJF-EMBL-CNRS, CS 90181, France., Vanderhoydonc F; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium., Munck S; VIB Bio Imaging Core and Center for the Biology of Disease, 3000 Leuven, Belgium.; KU Leuven - University of Leuven, Center for Human Genetics, 3000 Leuven, Belgium., Chaltin P; Cistim Leuven vzw, Bioincubator 2, 3001 Leuven, Belgium.; Centre for Drug Design and Discovery (CD3) KU Leuven R & D, Bioincubator 2, 3001 Leuven, Belgium., Swinnen JV; KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, 3000 Leuven, Belgium.
Publikováno v:
Oncotarget [Oncotarget] 2016 Mar 01; Vol. 7 (9), pp. 9975-92.
Autor:
De Gendt K; Laboratory of Experimental Medicine and Endocrinology, Catholic University of Leuven, Leuven, Belgium., Denolet E, Willems A, Daniels VW, Clinckemalie L, Denayer S, Wilkinson MF, Claessens F, Swinnen JV, Verhoeven G
Publikováno v:
Biology of reproduction [Biol Reprod] 2011 Nov; Vol. 85 (5), pp. 934-45. Date of Electronic Publication: 2011 Jul 06.